AVNS AVANOS MEDICAL, INC.

NYSE Orthopedic, Prosthetic & Surgical Appliances & Supplies DE CIK: 0001606498
AI RATING
SELL
72% Confidence

Investment Thesis

Despite a fortress balance sheet with low leverage (0.11x Debt/Equity) and solid 51.7% gross margins, Avanos suffers from fundamental operational deterioration including negative free cash flow of -$16.6M, stagnant revenue growth of 1.9%, and severely depressed returns on equity (0.7%) and assets (0.5%). The reported net income improvement appears disconnected from actual cash generation, signaling sustainability concerns.

Strengths

  • + Conservative capital structure with 0.11x Debt/Equity ratio and 2.48x current ratio provides substantial financial flexibility
  • + 51.7% gross margin demonstrates pricing power and product quality in medical devices market
  • + 81.4% year-over-year improvement in net income shows operational improvements relative to prior period

Risks

  • ! Negative free cash flow of -$16.6M with -9.1% FCF margin indicates the company is burning cash operationally, which is unsustainable long-term
  • ! Minimal revenue growth of 1.9% YoY reflects stagnant market position and limited expansion in orthopedic/surgical device markets
  • ! Extremely poor returns: ROE of 0.7% and ROA of 0.5% indicate severe capital inefficiency and value destruction for shareholders
  • ! Operating margin of only 4.9% and 2.8% net margin provide minimal cushion for unexpected challenges or market pressures
  • ! Interest coverage of 2.9x is adequate but leaves limited room for error if operational performance deteriorates further

Key Metrics to Watch

Financial Metrics

Revenue
182.2M
Net Income
5.1M
EPS (Diluted)
$0.11
Free Cash Flow
-16.6M
Total Assets
1.1B
Cash
65.6M

Profitability Ratios

Gross Margin 51.7%
Operating Margin 4.9%
Net Margin 2.8%
ROE 0.7%
ROA 0.5%
FCF Margin -9.1%

Balance Sheet & Liquidity

Current Ratio
2.48x
Quick Ratio
1.40x
Debt/Equity
0.11x
Debt/Assets
25.5%
Interest Coverage
2.87x
Long-term Debt
87.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T08:07:06.245110 | Data as of: 2026-03-31 | Powered by Claude AI